Avalo Therapeutics Inc (NAS:AVTX)
$ 9.55 -0.44 (-4.4%) Market Cap: 99.93 Mil Enterprise Value: 18.62 Mil PE Ratio: 0 PB Ratio: 4.39 GF Score: 47/100

Aytu BioScience Inc Acquires Prescription Product Portfolio from Cerecor Inc - M&A Call Transcript

Oct 14, 2019 / 08:30PM GMT
Operator

Good afternoon, everyone, and thank you for joining us for this conference call discussing Aytu BioScience's announced acquisition of a six-product commercial portfolio. With me this afternoon to discuss the details of the acquisition is Aytu's Chairman and Chief Executive Officer, Josh Disbrow.

Aytu BioScience issued a press release this morning announcing the acquisition with details describing the transaction. A copy of the press release is available on the news page of the Company's website at aytubio.com.

I'd like to remind everyone that today's call is being recorded. A replay of today's call will be available by using the telephone numbers and conference ID provided in the press release. In addition, a webcast will be accessible live and archived on Aytu BioScience's website within the investors section under events and presentations at aytubio.com.

Finally, I'd also like to call your attention to the customary Safe Harbor disclosure regarding forward-looking information. The conference call today will contain certain forward-looking statements, including statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot